Document is current
Any future updates will be listed below
-
Authors
Brydon, Jack
Krejcir, Radovan
Zavadil-Kokas, Filip
Singh, Ashita
Henek, Tomas
Hernychova, Lenka
Coleman, Skye
Al Shboul, Sofian
Hrabal, Vaclav
Kuncova, Zuzana
Mayordomo, Marcos Yébenes
Arcimowicz, Łukasz
Ball, Kathryn L.
Padariya, Monikaben
Kalathiya, Umesh
Vojtesek, Borivoj
Hupp, Ted
O’Neill, J. R.
-
Funding
Funding for this research was provided by:
BBSRC UK ((BB/J00751X/1).)
Salvage (CZ.02.01.01/00/22_008/0004644)
State Budget of the Czech Republic (MMCI, 00209805)
Polish high-performance computing infrastructure PLGrid (PLG/2024/017259)
Visegrad Fellowship Program of the International Visegrad Fund (62320160)
National Science Centre (2020/39/B/NZ7/02677)
Wellcome Trust clinical phd fellowship (094417/Z/10/Z)
CRUK Cambridge Cancer Centre Thoracic Cancer programme ((CTRQQR-2021\100012).)
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 16 December 2025
First Online: 10 March 2026
Declarations
:
: The use of the tumour array was under ethical approvals previously described [ ]. Clinical trial number: not applicable.
: BV is associated with Moravian Biotechnology as consultant, the company that developed the anti GPA33 polyclonal sera (Fig. A and B). The company did not provide financial support for the studies and had no influence on the design, execution or analysis of the experiments. The other authors declare that no competing interests exist.
